COVID-19 and renal infarct: To be or not to be on anticoagulation
| Autor: | Paola Devis, Chelsea Takamatsu, Ramin Tolouian |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
medicine.medical_specialty
Aspirin Castleman disease Coronavirus disease 2019 (COVID-19) spleen infarct business.industry Psychological intervention pulmonary emboli COVID-19 Case Report renal infarction medicine.disease Thrombosis Nephrology medicine arterial thrombi Geriatrics and Gerontology Intensive care medicine Risk assessment business anticoagulation Renal Infarct Thrombotic complication medicine.drug |
| Zdroj: | Clinical Nephrology. Case Studies |
| ISSN: | 2196-5293 |
| Popis: | We present a unique case of a male veteran with a history of Castleman disease, presenting with multiple arterial and venous vascular thromboses in the setting of recent Coronavirus (COVID-19)-disease diagnosis. We explore this patient's morbidity related to thrombotic complications of his COVID-19 diagnosis that were potentially avoidable with a comprehensive outpatient evaluation of his risk for thrombosis, as well as the initiation of anticoagulation and/or antiplatelet therapy given his high risk. Our case highlights the need for a standardized clinical workup of patients in the outpatient setting for risk assessment of vascular thrombosis associated with COVID-19 infection to direct medical management, in order to minimize adverse outcomes, complications requiring inpatient admission, and the need for additional yet limited medical resources and interventions. We propose a minimum of low-dose aspirin 81 mg daily as a reasonable approach for outpatient clinicians to consider, based on their best clinical judgement, when managing mild COVID-19, while other options, such as novel oral anticoagulants, are undergoing further investigation. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|